Clinical Studies Search

Protocol Summary


Protocol No.
PSCI-16-139
Prinicipal Investigator
Neves, Rogerio
Phase
Phase II
Age Group
Adult
Scope
National
Secondary Protocol No.
R2810-ONC-1620
Title
A Phase II Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Objective
The primary objective of the study is to estimate the ORR for Metastatic BCC or unresectable locally advanced BCC according to central review when treated with REGN2810 monotherapy in patients who have progressed on or were intoerant of previous HHI therapy.
Applicable Disease Sites
Other Skin
Therapies Involved
Chemotherapy (NOS)
Drugs Involved
REGN2810
Status
Open
Participating Institutions
Hershey Medical Center